<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005857</url>
  </required_header>
  <id_info>
    <org_study_id>99118</org_study_id>
    <secondary_id>U01CA063265</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-PHII-19</secondary_id>
    <secondary_id>CHNMC-IRB-99118</secondary_id>
    <secondary_id>NCI-T98-0090</secondary_id>
    <secondary_id>CDR0000067884</secondary_id>
    <nct_id>NCT00005857</nct_id>
  </id_info>
  <brief_title>Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy</brief_title>
  <official_title>Randomized Phase II Trial of Herceptin (NSC 688097) and Weekly Docetaxel (NSC 628503) in Androgen-Independent (Horomone Refractory) Adenocarcinoma of the Prostate (CaP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill&#xD;
      them or deliver tumor-killing substances to them without harming normal cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to compare the effectiveness of trastuzumab alone and in combination&#xD;
      with docetaxel in treating patients who have metastatic prostate cancer that is refractory to&#xD;
      hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy and toxicity of docetaxel (arm I) vs trastuzumab (Herceptin) (arm&#xD;
           II), followed by a combination of docetaxel and trastuzumab in patients with&#xD;
           androgen-independent or hormone-refractory metastatic, Her2/neu-positive prostate&#xD;
           cancer. (Arm I closed to accrual effective 07/30/2001.)&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Arm I: Patients receive docetaxel IV over 1 hour weekly for 6 weeks. Treatment continues&#xD;
           every 8 weeks for at least 2 courses in the absence of unacceptable toxicity. (Arm I&#xD;
           closed to accrual effective 07/30/2001. Arm I patients crossover to arm II.)&#xD;
&#xD;
        -  Arm II: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes weekly for 8&#xD;
           weeks. Treatment continues every 8 weeks for at least 2 courses in the absence of&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients with progressive or stable disease after 2 courses of single-agent therapy receive&#xD;
      docetaxel IV over 1 hour on day 1 of each week for 6 consecutive weeks and trastuzumab IV&#xD;
      over 30-90 minutes on day 1 of each week for 8 consecutive weeks. Treatment continues every 8&#xD;
      weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with complete or partial response to single-agent therapy continue on that therapy&#xD;
      until experiencing progressive or stable disease. The patients then proceed to combination&#xD;
      therapy.&#xD;
&#xD;
      Patients are followed until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 108-160 patients (54-80 per treatment arm) will be accrued for&#xD;
      this study. (Arm I closed to accrual effective 07/30/2001.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV prostate cancer (any T, any N, M1, any G; D3)&#xD;
&#xD;
          -  Clinical evidence of metastatic disease in bone or soft tissue&#xD;
&#xD;
          -  Her2/neu-positive (2+ and 3+) by immunochemistry or fluorescent in situ hybridization&#xD;
&#xD;
          -  Androgen-independent&#xD;
&#xD;
               -  Serum PSA at least 10 ng/mL that has risen on 3 successive evaluations after&#xD;
                  prior hormonal therapy&#xD;
&#xD;
               -  At least 1 month since prior antiandrogen therapy (e.g., flutamide, bicalutamide,&#xD;
                  or nilutamide) and rising PSA levels with 1 of the 2 rising PSA levels, measured&#xD;
                  at least 2 weeks apart, after antiandrogen withdrawal&#xD;
&#xD;
          -  Bone only disease and elevated PSA alone allowed&#xD;
&#xD;
          -  LHRH analog therapy must continue in patients who have not had prior orchiectomy and&#xD;
             have castrate levels of testosterone&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,800/mm3&#xD;
&#xD;
          -  Platelet count at least lower limit of normal (LLN)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction more than 50% or more than LLN by MUGA scan or 2-D echocardiogram&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No active ischemia on EKG&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated basal cell&#xD;
             or squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than one prior nonanthracycline chemotherapy regimen (including suramin)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent corticosteroids as antiemetic&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior strontium chloride Sr 89 and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy to measurable lesions&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Primo N. Lara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center and Beckman Research Institute, City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center of Boston</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15;100(10):2125-31. doi: 10.1002/cncr.20228.</citation>
    <PMID>15139054</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>August 28, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2003</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

